NCT00411723View on ClinicalTrials.gov

Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis

PHASE1UnknownINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

May 31, 2009

Conditions
Multiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

RTL1000 (recombinant T cell receptor ligand)

Dosage form: IV infusion. Dosage: Single dose @ 2, 6, 20, 60, 100 or 200mg. Duration: 1 - 2 hours.

DRUG

RTL1000 Placebo

Dosage form: IV infusion. Dosage: Same volume as Experimental. Frequency: Single dose. Duration: 1 - 2 hours.

Trial Locations (6)

21201

University of Maryland School of Medicine, Baltimore

46202

Indiana University, Dept. of Neurology, Indianapolis

66160

University of Kansas Medical Center, Landon Center on Aging, Kansas City

97239

MS Center of Oregon Health & Science University, Portland

98034

MS Center at Evergreen, Kirkland

06510

Yale Center for MS Treatment and Research, New Haven

Sponsors
All Listed Sponsors
lead

Artielle ImmunoTherapeutics

INDUSTRY

NCT00411723 - Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis | Biotech Hunter | Biotech Hunter